Hepatocellular carcinoma is a formidable malignancy with rising incidence rates globally. Its insidious nature often leads to late-stage diagnosis and poor prognosis for patients. As researchers strive to develop effective therapeutic strategies, the focus has slowly shifted from conventional pharmacological agents to natural products. In this context, studies highlighting the unique properties of ginsenoside RG3 and cantharidin have emerged, mapping out novel pathways that could be leveraged for therapeutic gain.

The combination of ginsenoside RG3 and cantharidin presents a novel approach to HCC treatment by targeting critical metabolic pathways. Recent research has revealed that the two compounds work synergistically, amplifying each other’s effects which, in turn, provides a more comprehensive attack on cancer cells. The intricate mechanism of this synergism lies within its ability to influence lipid metabolism, an essential aspect of cancer cell survival and proliferation.

A decisive finding of this research is the focus on the PRMT1-SREBF1 axis. Protein arginine methyltransferase 1 (PRMT1) is a crucial regulator involved in various cellular processes, including gene expression and lipid metabolism. In HCC, aberrant activity of PRMT1 contributes to metabolic dysregulation that favors cancer progression. Interestingly, ginsenoside RG3 and cantharidin appear to modulate the activity of PRMT1, demonstrating a promising mechanism through which these natural products may suppress tumor growth.

SREBF1, or sterol regulatory element-binding protein 1, is a transcription factor that plays a pivotal role in cholesterol homeostasis and fatty acid metabolism. In cancer, elevated SREBF1 can drive lipid biosynthesis, thereby fueling tumor growth. Targeting the PRMT1-SREBF1 pathway provides a strategic point of intervention. By inhibiting PRMT1’s activity with ginsenoside RG3 and cantharidin, researchers are able to downregulate SREBF1, leading to reduced lipid synthesis in cancer cells.

One of the most critical aspects of this combined treatment regimen is its ability to lead to apoptosis in HCC cells. Apoptosis, or programmed cell death, is a natural process that eliminates damaged or unregulated cells. The research underscores that ginsenoside RG3 and cantharidin disrupt pro-survival signaling pathways within HCC cells, prompting these malignant cells to undergo apoptosis. This effect positions the combination therapy as not merely a growth inhibitor, but as a potential agent of cancer cell death.

Furthermore, studies have begun to explore the implications of this dual therapy not only in vitro but also in vivo. Animal models of HCC are becoming instrumental in understanding the real-world efficacy of ginsenoside RG3 and cantharidin. Preliminary results suggest that treatment with these compounds significantly reduces tumor burden and metastasis, an exciting prospect for future clinical applications.

This research also emphasizes the importance of understanding the pharmacokinetics and dynamics of ginsenoside RG3 and cantharidin. The bioavailability and metabolic stability of these compounds need to be carefully evaluated to enhance their therapeutic potential. Investigators are keenly analyzing how these substances are absorbed, distributed, metabolized, and excreted in the body to optimize their use in clinical settings.

In addition to their direct anti-cancer effects, the therapeutic potential of natural compounds extends beyond traditional cytotoxicity. Ginsenoside RG3 and cantharidin may possess immunomodulatory effects that enhance the body’s own defense mechanisms against cancer. This dual action—targeting cancer cells while orchestrating a robust immune response—elevates their potential as integral components of a multifaceted treatment approach in modern oncology.

The implications derived from this research are profound, as they align seamlessly with the growing narrative of precision medicine and personalized treatment paradigms in cancer care. With a focus on the individual patient’s genetic, molecular, and metabolic profiles, the synergistic effects of ginsenoside RG3 and cantharidin could be tailored for optimized outcomes.

As research continues to evolve in its exploration of these natural compounds, the scientific community is urged to maintain an open dialogue about their enormous potential. The emergence of synergistic therapies represents a pivotal shift in managing complex diseases such as HCC, which have remained stubbornly resistant to conventional treatments.

Dr. Yuan and colleagues’ study emphasizes the need for further in-depth investigations into the mechanisms underlying the observed effects. Future work will be critical in elucidating the precise interaction sites and cellular pathways involved in the combined treatment effects of ginsenoside RG3 and cantharidin.

In conclusion, the synergistic effects of ginsenoside RG3 and cantharidin on hepatocellular carcinoma illustrate a significant stride towards a broader understanding of cancer treatment. By targeting the PRMT1-SREBF1 axis and other integral pathways, researchers are laying the groundwork for new, effective therapies that could ultimately change the landscape of oncological care. As promising results continue to emerge, the scientific community stands on the precipice of potentially revolutionary new approaches to combat HCC, underscoring the importance of natural compounds in the ongoing battle against cancer.

Subject of Research: Synergistic effects of ginsenoside RG3 and cantharidin in hepatocellular carcinoma.

Article Title: Ginsenoside RG3 and cantharidin synergistically suppress the progression of hepatocellular carcinoma via targeting the PRMT1-SREBF1 axis-mediated lipid metabolism.

Article References:

Wang, Y., Yuan, H., Yu, Y. et al. Ginsenoside RG3 and cantharidin synergistically suppress the progression of hepatocellular carcinoma via targeting the PRMT1-SREBF1 axis-mediated lipid metabolism.
J Transl Med (2026). https://doi.org/10.1186/s12967-025-07550-8

Image Credits: AI Generated

DOI: 10.1186/s12967-025-07550-8

Keywords: Hepatocellular carcinoma, ginsenoside RG3, cantharidin, PRMT1, SREBF1, lipid metabolism, apoptosis, cancer therapy.

Hepatocellular carcinoma, the most common primary liver cancer, often strikes patients who retain relatively preserved liver function. Despite advances in cancer therapy, liver transplantation remains a cornerstone treatment for early-stage HCC, conferring improved survival and disease control. Yet, the gap between transplant demand and available organs forces many patients into extended waiting periods, with increased risk of tumor progression and mortality. The RAPID-HCC trial, a prospective, multicenter study spanning five top university hospitals in France, was conceived to rigorously evaluate whether the RAPID procedure can break these barriers.

At the heart of this innovative surgical technique lies the concept of split liver transplantation from deceased donors. Traditionally, whole liver grafts from brain-dead donors are transplanted into recipients. However, the RAPID procedure divides one donor liver into two segments, enabling simultaneous transplantation into two adult recipients. The trial specifically enrolls adult HCC patients with preserved liver function, defined by MELD scores of 15 or below, to receive the left lateral lobe (segments II and III) as a living graft replacement for their marginal native liver.

The surgical process of the RAPID procedure unfolds in a meticulously timed two-phase operation. Initially, the donor’s left lateral segment is meticulously split and transplanted to replace the recipient’s left liver lobe, while the patient’s native right liver lobe remains intact to sustain hepatic function. This partial augmentation provides immediate functional support, allowing the patient’s physiology to adapt gradually. After a period of roughly four months, the native right lobe is removed in a delayed sequential hepatectomy, effectively transitioning the graft to full function.

Trial enrolment targets 50 adult HCC patients, among whom 34 are designated to undergo the RAPID procedure with split liver grafts. This multicentric study adopts rigorous criteria for patient selection and perioperative care to assess not only feasibility but also safety, tolerance, and overall efficacy. Primary endpoints focus on successful completion of both surgical stages and incidence of adverse events, while secondary measures examine crucial outcomes such as graft survival, patient survival, incidence of rejection, HCC recurrence, and comparative waiting times versus conventional whole liver transplantation.

Prior observational studies have hinted at the potential benefits of the RAPID technique. By maximizing the utility of a single donor organ among two recipients, the method significantly bolsters graft availability, potentially curtailing the current organ deficit crisis. For patients, this could translate into shorter waiting times, earlier transplantation, and consequently lower risk of tumor progression or dropout from the transplant list. However, quantitative evidence from robust prospective trials such as RAPID-HCC remains necessary to validate these promising early indications.

The RAPID-HCC trial carries profound implications for transplant medicine, especially for patients with HCC who are often caught in the precarious balance between liver function reserve and cancer progression. By targeting patients with preserved liver function, the trial leverages their native hepatic support as a safety buffer during the transplantation transition. This strategic approach contrasts with traditional transplant methodologies that replace the entire liver simultaneously, thereby potentially reducing surgical risk and postoperative complications.

Crucially, the delayed total hepatectomy aspect offers a novel pathway for the transplanted graft to gradually assume full functional responsibility. By staging the liver removal process, the patient’s hepatocyte function adapts progressively, minimizing risks associated with sudden hepatic failure or graft insufficiency. The physiological dynamics underpinning this gradual shift are being closely monitored through the study, offering valuable mechanistic insights into liver regeneration and adaptation post-transplant.

The prospective, non-randomized design across multiple high-volume centers in France ensures that data emerging from RAPID-HCC will reflect real-world applicability with diverse surgical teams and patient populations. Rigorous follow-up protocols will capture clinical outcomes including patient survival at various time points, graft function, rejection episodes governed by immunological assays, and cancer recurrence monitored via imaging and biomarkers. The wealth of data will help delineate the exact performance metrics and potential complications inherent to this new surgical paradigm.

While the RAPID technique offers exciting opportunities, challenges remain. Technical complexity in splitting the liver graft and orchestrating two separate yet coordinated surgeries demands high surgical expertise and interdisciplinary coordination. Additionally, close management of immunosuppressive therapy and vigilant monitoring for rejection phenomena are necessary to safeguard graft longevity. The trial’s comprehensive protocol is designed to address these intricacies through standardized operative and postoperative care pathways.

If successful, RAPID-HCC could redefine the transplant landscape, setting a new standard of practice by systematically expanding donor liver utilization and reducing mortality among HCC candidates. Moreover, the principles underpinning this approach may extend beyond HCC to other liver diseases amenable to partial transplantation strategies, magnifying its clinical impact globally.

This investigation is backed by the French national PHRC-K Inca 2020 grant, marking a significant investment in innovative liver transplant research. Registered under ClinicalTrials.gov (NCT05971628) before patient recruitment commenced, the trial exemplifies rigorous scientific transparency and adherence to ethical research standards. The consortium of transplant surgeons, oncologists, and hepatologists driving RAPID-HCC is poised to pioneer a transformative chapter in hepatic oncology and transplantation.

Ultimately, the RAPID procedure embodies a fusion of surgical ingenuity and clinical necessity, striving to reconcile the glaring mismatch between organ demand and supply. Its focus on timed, partial transplantation with delayed total hepatectomy creates a dynamic clinical model that balances risk, function, and oncologic control. As data accrues from this landmark trial, the transplant community worldwide keenly anticipates validation that could usher in a new era of liver transplant strategy for HCC patients.

In a field where innovation is deeply intertwined with patient survival, the RAPID-HCC trial is a beacon of hope—offering a pragmatic solution to one of the most stubborn bottlenecks in transplant medicine. Its pioneering approach challenges traditional doctrines, harnessing split grafts not only to increase organ availability but also to improve functional outcomes, thereby reshaping the future for thousands waiting for life-saving liver transplants.

As transplantation science progresses, studies like RAPID-HCC underscore the critical importance of adaptive surgical techniques informed by robust clinical trials. With liver cancer incidence rising globally and organ scarcity worsening, the timely results from this trial will be pivotal in guiding policies, surgical practices, and patient care pathways on a global scale.

The RAPID procedure is poised to become more than a novel technique; it represents a potential paradigm shift in how surgeons and clinicians approach one of the deadliest liver diseases. By expanding the boundaries of partial transplantation through staged hepatectomy, the method elegantly integrates regenerative biology with surgical precision, ultimately aiming to save lives and improve quality of life for patients with hepatocellular carcinoma.

Subject of Research: Liver transplantation for hepatocellular carcinoma using the RAPID procedure involving resection and partial liver transplantation from deceased donors.

Article Title: Resection and partial liver transplantation from deceased donors with delayed total hepatectomy (RAPID procedure) for hepatocellular carcinoma: a national, multicenter, non-randomized, prospective trial

Article References:
Peloso, A., Pietrasz, D., Daillier, E. et al. Resection and partial liver transplantation from deceased donors with delayed total hepatectomy (RAPID procedure) for hepatocellular carcinoma: a national, multicenter, non-randomized, prospective trial. BMC Cancer 25, 848 (2025). https://doi.org/10.1186/s12885-025-14127-7

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14127-7